- In a retrospective study of patients with atopic dermatitis (AD) treated with dupilumab, 4.2% experienced de novo or aggravated head and neck dermatitis (HN-D).
Why this matters
- HN-D is a novel adverse event that may be explained by dysregulation of T-cell signaling.
- 42 patients (4.2%) experienced HN-D (aggravation, 3.2%; de novo symptoms, 1.0%).
- HN-D happened a median of 65.4 days (range, 5-365 days) after initiating dupilumab.
- Of HN-D-affected patients, 43% had ocular involvement before dupilumab therapy, and 48% had concomitant ocular adverse effects under dupilumab treatment.
- Of patients with HN-D treated with topical therapy, 52.4% experienced improvement, 19.0% experienced aggravation, and 11.9% experienced persistence.
- 5 of 42 patients with HN-D (11.9%) had to discontinue dupilumab.
- 1000 patients with AD treated with dupilumab from 29 centers were included.
- Funding: None disclosed.
- Retrospective analysis.